The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients.
By Reuters
Share
Save
Save articles to read later and create your own reading list.
Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage
Trump announces deal to lower prices for obesity drugs - UPI.com
Trump Says Obesity Drugmakers Will Cut GLP-1 Prices—Medicare Will Cover Some Costs
Trump unveils deals to lower US weight-loss drug prices
Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk
Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk
Trump, accordo per farmaci antiobesità alla portata di tutti
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic | Fortune
US to slash prices of obesity drugs offered on Trump website
Pfizer beats out Novo Nordisk in bidding for obesity drugmaker Metsera | Fortune
The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in high…
Eli Lilly and Novo Nordisk officials have agreed to lower the cost of GLP-1 obesity drugs for Medicaid and Medicare recipients…
The deal also means Medicare will start covering obesity drugs for some patients for the first time beginning next year.
US President Donald Trump announces agreements with drug makers Eli Lilly and Novo Nordisk.
Eli Lilly and Novo Nordisk shares dropped after President Donald Trump said he wants a $150 price tag for GLP-1s.
Medicare will start covering obesity drugs for the first time, which could open access to millions of seniors and spur more…
